Literature DB >> 11223200

Immunoconversion against Sarcocystis neurona in normal and dexamethasone-treated horses challenged with S. neurona sporocysts.

T J Cutler1, R J MacKay, P E Ginn, K Gillis, S M Tanhauser, E V LeRay, J B Dame, E C Greiner.   

Abstract

Equine protozoal myeloencephalitis is a common neurologic disease of horses in the Americas usually caused by Sarcocystis neurona. To date, the disease has not been induced in horses using characterized sporocysts from Didelphis virginiana, the definitive host. S. neurona sporocysts from 15 naturally infected opossums were fed to horses seronegative for antibodies against S. neurona. Eight horses were given 5x10(5) sporocysts daily for 7 days. Horses were examined for abnormal clinical signs, and blood and cerebrospinal fluid were harvested at intervals for 90 days after the first day of challenge and analyzed both qualitatively (western blot) and quantitatively (anti-17kDa) for anti-S. neurona IgG. Four of the challenged horses were given dexamethasone (0.1mg/kg orally once daily) for the duration of the experiment. All challenged horses immunoconverted against S. neurona in blood within 32 days of challenge and in CSF within 61 days. There was a trend (P = 0.057) for horses given dexamethasone to immunoconvert earlier than horses that were not immunosuppressed. Anti-17kDa was detected in the CSF of all challenged horses by day 61. This response was statistically greater at day 32 in horses given dexamethasone. Control horses remained seronegative throughout the period in which all challenged horses converted. One control horse immunoconverted in blood at day 75 and in CSF at day 89. Signs of neurologic disease were mild to equivocal in challenged horses. Horses given dexamethasone had more severe signs of limb weakness than did horses not given dexamethasone; however, we could not determine whether these signs were due to spinal cord disease or to effects of systemic illness. At necropsy, mild-moderate multifocal gliosis and neurophagia were found histologically in the spinal cords of 7/8 challenged horses. No organisms were seen either in routinely processed sections or by immunohistochemistry. Although neurologic disease comparable to naturally occurring equine protozoal myeloencephalitis (EPM) was not produced, we had clear evidence of an immune response to challenge both systemically and in the CNS. Broad immunosuppression with dexamethasone did not increase the severity of histologic changes in the CNS of challenged horses. Future work must focus on defining the factors that govern progression of inapparent S. neurona infection to EPM.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11223200     DOI: 10.1016/s0304-4017(00)00420-9

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  4 in total

Review 1.  An update on Sarcocystis neurona infections in animals and equine protozoal myeloencephalitis (EPM).

Authors:  J P Dubey; D K Howe; M Furr; W J Saville; A E Marsh; S M Reed; M E Grigg
Journal:  Vet Parasitol       Date:  2015-02-07       Impact factor: 2.738

2.  Phylogenetic congruence of Sarcocystis neurona Dubey et al., 1991 (Apicomplexa: Sarcocystidae) in the United States based on sequence analysis and restriction fragment length polymorphism (RFLP).

Authors:  Hany M Elsheikha; Alice J Murphy; Linda S Mansfield
Journal:  Syst Parasitol       Date:  2005-07       Impact factor: 1.431

3.  Dexamethasone treatment induces susceptibility of outbred Webster mice to experimental infection with Besnoitia darlingi isolated from opossums (Didelphis virginiana).

Authors:  Hany M Elsheikha; Benjamin M Rosenthal; Linda S Mansfield
Journal:  Parasitol Res       Date:  2005-03-10       Impact factor: 2.289

Review 4.  Equine Protozoal Myeloencephalitis: An Updated Consensus Statement with a Focus on Parasite Biology, Diagnosis, Treatment, and Prevention.

Authors:  S M Reed; M Furr; D K Howe; A L Johnson; R J MacKay; J K Morrow; N Pusterla; S Witonsky
Journal:  J Vet Intern Med       Date:  2016-02-09       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.